Avant Diagnostics, Inc — Form D
Avant Diagnostics, Inc of WASHINGTON, DC, a company, filed a Form D exempt-offering notice with the SEC on 2018-06-13. The offering totals $2.0M, of which $1.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-06-13
- Form: D
- Accession: 0001213900-18-007578
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.0M
- Amount sold: $1.2M
- Remaining: $835K
- Minimum investment: $100K
- Investors: 8
- Date of first sale: 2018-05-25
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-314464
Issuer
- Name: Avant Diagnostics, Inc
- CIK: 0001451929
- Entity type: Corporation
- Jurisdiction: NEVADA
- Address: 1050 30TH STREET NW, SUITE 107, WASHINGTON, DC, 20007
- Phone: 708-710-9200
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| John Brugmann | Director | Washington, DC |
| Jeff Busch | Director | Washington, DC |
| Jeff Stephens | Director | Washington, DC |
| Robert Trapp | Director | New York, NY |
| Michael Ruxin, M.D. | Executive Officer | Washington, DC |
| Scott VanderMeer | Executive Officer | Chicago, IL |
| Randall Letcavage | Director | TUSTIN, CA |
| Gregg Linn | Director | Scottsdale, AZ |
| Gregg Linn | Executive Officer | Scottsdale, AZ |
| Joseph Roth | Director | Scottsdale, AZ |
Other filings by this issuer (1)
More